{"groups":[{"description":"Pharmacists included in Nikkei Medical Online Panel, active in clinical practice, and with valid contact details who belonged to hospitals and have instructed the dosing of NINLARO (ixazomib) in combination with lenalidomide and dexamethasone (IRD therapy) to patients were selected to participate in the survey.","id":"FG000","title":"Pharmacists in Hospitals Prescribing NINLARO"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"330"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"330"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 24,000 pharmacists were requested to cooperate. Of these, 1329 pharmacists consented to participate in this study and 336 pharmacists passed the screening questions, out of which 6 pharmacists did not complete the questionnaire. 330 pharmacists were enrolled and completed all questions and were included in the analysis.","recruitmentDetails":"Recruitment and response collection started on 01 June 2023 and ended on 09 June 2023."}